Second-line chemotherapy in advanced bladder cancer

Urol Int. 2000;64(2):61-9. doi: 10.1159/000030493.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / genetics
  • Carcinoma, Transitional Cell / secondary
  • Cisplatin / administration & dosage
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Doxorubicin / administration & dosage
  • Female
  • Genes, p53
  • Humans
  • Male
  • Methotrexate / administration & dosage
  • Middle Aged
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / genetics
  • Vinblastine / administration & dosage

Substances

  • Vinblastine
  • Doxorubicin
  • Cisplatin
  • Methotrexate

Supplementary concepts

  • M-VAC protocol